Abstract:Primary hyperoxaluria type 1 (PH1) is a rare and severe autosomal recessive disease of oxalate metabolism, resulting from a mutation in the AGXT gene that encodes the hepatic peroxisomal enzyme alanine-glyoxylate aminotransferase (AGT). Until recently, treatment of PH1 was supportive, consisting of intensive hyperhydration, use of crystallization inhibitors (citrate and neutral phosphorus), in a subset of responsive PH1 patients' pharmacologic doses of vitamin B6 (pyridoxine), and kidney and liver transplantation when patients progressed to kidney failure. Treatment approaches have been similar for PH2 caused by mutations in hepatic glyoxylate reductase/hydroxypyruvate reductase (GR/HPR), although pyridoxine does not have any benefit in this group. PH3 is caused by mutations of mitochondrial 4-hydroxy-2-oxoglutarate aldolase (HOGA1) and was the most recently described. Kidney failure appears less common in PH3, although kidney stones occur as frequently as in PH1 and PH2. Oxalate metabolism in the liver is complex. Novel therapies based on RNA interference (RNAi) have recently emerged to modulate these pathways, designed to deplete substrate for enzymes upstream and decrease/avoid oxalate production. Two hepatic enzymes have been targeted to date in PH: glycolate oxidase (GO) with lumasiran and lactate dehydrogenase A (LDH-A) with nedosiran. Lumasiran was approved for the treatment of PH1 in 2020 by both the European Medicines Agency and the Food and Drug Administration, whilst clinical trials with nedosiran are ongoing. Results with the two RNAi therapies demonstrate a significant reduction of urinary oxalate excretion in PH1 patients, but long-term data on efficacy (preservation of kidney function, decreased stone events) and safety remain to be established. Nevertheless, the hepatically targeted RNAi approach represents a potential 'game changer' in the field of PH1, bringing hope to families and patients that they may be able to avoid liver and/or kidney transplantation in the future and suffer fewer stone events, perhaps with less strict therapeutic regimens. Pharmacological compounds directly inhibiting GO or LDH are also under development and could be of special interest in developing countries where RNAi therapies may not be readily available in the near future. Approaches to manipulate the intestinal microbiome with a goal to increase oxalate degradation or to stimulate secretion of oxalate into the intestine from plasma are also under development. Overall, we appear to be entering a new phase of PH treatment, with an array of promising approaches emerging that will need optimization and evaluation to establish long-term efficacy and safety.

Simultaneous or sequential kidney-liver transplantation in primary hyperoxaluria

Outcomes of Liver–kidney Transplantation in Patients with Primary Hyperoxaluria: an Analysis of the Scientific Registry of Transplant Recipients Database

Multidisciplinary Cooperation in a Simultaneous Combined Liver and Kidney Transplantation Patient of Primary Hyperoxaluria 1.

Subsequent Liver Transplantation Did Not Reverse Recurrence of Oxalate Nephropathy after Isolated Kidney Transplantation for Primary Type 2 Hyperoxaluria

Primary hyperoxaluria: Long-term outcomes of isolated kidney versus simultaneous liver/kidney transplant

Transplantation Procedures in Children with Primary Hyperoxaluria Type 1: Outcome and Longitudinal Growth

Primary hyperoxaluria type 1: novel therapies at a glance

Primary Hyperoxaluria Diagnosed after Kidney Transplantation Failure: Lesson from 3 Case Reports and Literature Review

Bone health in children with primary hyperoxaluria type 1 following liver and kidney transplantation

Second transplantation after kidney graft loss in primary hyperoxaluria type 2: a pedigree study and mutation analysis

Simultaneous Liver-Kidney Transplantation in Polycystic Kidney and Hepatic Disease with Kidney and Liver Failure

Reversal of oxalosis cardiomyopathy after combined liver and kidney transplantation

Unilateral Crystalline Ischemic Retinopathy Secondary to Primary Hyperoxaluria with Renal Failure and Oxalosis

Liver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome

Navigating the Evolving Landscape of Primary Hyperoxaluria: Traditional Management Defied by the Rise of Novel Molecular Drugs

Transplantation for infantile nephronophthisis with loss-of-function mutation in NPHP3: Lesson from a case

Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption

Infant primary hyperoxaluria type 1 : A case report and literature review

Anesthetic support in synchronous liver and kidney transplantation

Lumasiran for Primary Hyperoxaluria Type 1: What We Have Learned?

Lumasiran: expanding the treatment options for patients with primary hyperoxaluria type 1